

Global Huntington's Disease Market - 2025-2033

<https://marketpublishers.com/r/G2BF0B653A37EN.html>

Date: May 2025

Pages: 168

Price: US\$ 4,350.00 (Single User License)

ID: G2BF0B653A37EN

Abstracts

Global Huntington's Disease Market - Overview

The global Huntington's disease market size reached US\$ 455.65 million in 2024 and is expected to reach US\$ 3,230.84 million by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.

The Huntington's disease market is being driven by increasing research and development efforts focused on innovative therapies, alongside growing public awareness and education about the disorder. North America is expected to maintain a leading position in the global market due to strong healthcare infrastructure and ongoing clinical advancements, while the Asia-Pacific region is projected to experience the fastest growth, supported by expanding healthcare access and rising investment in neurological research.

Global Huntington's Disease Market Dynamics - Drivers & Restraints

Rising Research and Development is Expected to Propel the Huntington's Disease Market

With increased focus on the genetic basis of the disease, therapies such as gene silencing and antisense oligonucleotides (ASOs), pharmaceutical companies, and research institutions continue to advance innovative therapeutic strategies. For instance, in June 2024, Wave Life Sciences announced encouraging results from its Phase 1b/2a SELECT-HD trial of WVE-003, an allele-selective ASO designed to reduce mutant huntingtin (mHTT) protein while preserving healthy wild-type HTT. The therapy showed a 46% reduction in mHTT in cerebrospinal fluid compared to placebo and demonstrated a significant correlation with slower brain atrophy, a biomarker linked to disease progression.

Additionally, organizations continue to invest heavily in HD research, accelerating the development of disease-modifying treatments. For instance, in January 2025, Brain Canada, the Huntington Society of Canada (HSC), and the River Philip Foundation jointly announced a new investment of \$1.2 million to support research focused on Huntington's disease. These advancements are expanding the therapeutic landscape and attracting regulatory interest, positioning R&D as a key force driving future growth in the Huntington's disease market.

Huntington's Disease Approved Drugs:

High Cost of Treatment is Expected to Hamper the Huntington's Disease Market

The high cost of treatment could limit patient access and place a substantial financial burden on healthcare systems. Currently available therapies, such as Austedo (deutetrabenazine) and Xenazine (tetrabenazine), which are used to manage symptoms like chorea, can cost tens of thousands of dollars annually. These factors are expected to have a significant impact on the overall market growth.

Global Huntington's Disease Market - Segment Analysis

The global Huntington's disease market is segmented based on disease type, treatment, route of administration, and region.

Treatment:

The symptomatic treatment segment is expected to hold 52.4% of the global Huntington's disease market

The symptomatic treatment segment is expected to dominate the Huntington's disease market due to the well-established role of medications in managing hallmark symptoms, particularly chorea. Drugs such as Xenazine (tetrabenazine) and Austedo (deutetrabenazine) remain first-line therapies, offering substantial improvements in quality of life by reducing involuntary movements.

For instance, in Q2 2024, Teva Pharmaceutical Industries reported a 32% increase in quarterly U.S. sales of Austedo, reaching \$407 million, highlighting its strong market demand and clinical relevance. Moreover, for instance, in August 2023, the FDA approved INGREZZA (valbenazine), developed by Neurocrine Biosciences, for the

treatment of chorea associated with Huntington's disease, further reinforcing the strength and expansion of symptomatic treatment options.

This dominance is further supported by disease prevalence data. For instance, according to the National Institute of Health in 2022, the diagnosed prevalence was estimated to be 8.2 to 9.0 per 100,000 in the United States. The growing pipeline of symptomatic therapies and their proven effectiveness make this segment likely to retain the largest market share as demand for symptom relief continues to rise.

Global Huntington's Disease Market - Geographical Analysis

North America is expected to hold 39.7% of the global Huntington's disease market

North America is expected to maintain a dominant position in the global Huntington's disease (HD) treatment market due to its advanced healthcare infrastructure, high disease prevalence, and continuous research advancements. In recent years, significant developments in the region have further solidified this position. The U.S. Food and Drug Administration (FDA) has approved several treatments for symptomatic management of HD, including Austedo and Xenazine.

More recently, in August 2023, the FDA approved INGREZZA (valbenazine) for treating chorea associated with HD, based on positive results from the KINECT-HD Phase 3 study.

Additionally, companies are strategically partnering with each other to become prominent players in the market. For instance, UniQure reached an agreement with the FDA in December 2024 for the potential accelerated approval of its gene therapy AMT-130, aimed at addressing the root cause of HD.

Moreover, in December 2024, PTC Therapeutics partnered with Novartis in a licensing agreement valued at up to \$2.9 billion for the development of PTC518, a drug targeting the mutated Huntingtin protein.

These efforts, along with proactive organizations like the Huntington Society of Canada, which works to train neurologists and improve care, position North America as a leader in advancing the treatment landscape for Huntington's disease.

Asia-Pacific is expected to hold 25.6% of the global Huntington's disease market

The Asia-Pacific is expected to be the fastest-growing region in the Huntington's disease market. This growth is attributed to the rising disease awareness, improved healthcare infrastructure, and increasing funding in research and therapeutic trials are major contributions.

Global Huntington's Disease Market - Competitive Landscape

Manufacturers

Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., and Neurocrine Biosciences, Inc., among others.

Global Huntington's Disease Market - Key Developments

In September 2023, Ionis Pharmaceuticals, Inc. announced a collaboration with Roche focused on an early-stage RNA-targeting investigational therapy for Huntington's disease. Under the agreement, Roche will have exclusive global rights and will lead clinical development, manufacturing, and commercialization if the treatment is approved. The partnership combines Ionis' RNA-based drug discovery expertise with Roche's global capabilities in neurological therapeutics.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.

Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.

Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.

Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.

Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.

Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.

Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.

Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.

Regional Growth & Investment: Highlights high-growth regions and investment opportunities.

Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.

Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.

Post-market Surveillance: Uses post-market data to enhance product safety and access.

Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Huntington's disease market report delivers a detailed analysis with 57 key tables, more than 46 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.

Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.

Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical

Trial Managers, Pharmacovigilance Experts.

Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.

Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.

Supply Chain: Distribution and Supply Chain Managers.

Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.

Academic & Research: Academic Institutions.

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Disease Type
- 2.4. Snippet by Treatment
- 2.5. Snippet by Route of Administration
- 2.6. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Research and Development
 - 3.1.1.2. Rising Awareness and Patient Advocacy
 - 3.1.1.3. XX
 - 3.1.2. Restraints
 - 3.1.2.1. High Cost of Treatment
 - 3.1.2.2. Stringent Regulatory Framework
 - 3.1.2.3. XX
 - 3.1.3. Opportunity
 - 3.1.3.1. Expansion into Emerging Markets
 - 3.1.3.2. XX
 - 3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established Leaders with the Largest Marketing Brand
 - 4.1.3. Market Leaders with Established Products

- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape
 - 4.3.1. North America
 - 4.3.2. Europe
 - 4.3.3. Asia Pacific
 - 4.3.4. Latin America
 - 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
- 4.5. Supply Chain Analysis
- 4.6. Patent Analysis
- 4.7. SWOT Analysis
- 4.8. Pipeline Analysis
- 4.9. Epidemiology Analysis
- 4.10. Unmet Needs and Gaps
- 4.11. Recommended Strategies for Market Entry and Expansion
- 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 4.13. Pricing Analysis and Price Dynamics
- 4.14. Key Opinion Leaders

5. HUNTINGTON'S DISEASE MARKET DISEASE TYPE OUTLOOK

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
 - 5.1.2. Market Attractiveness Index, By Disease Type
- 5.2. Adult Onset*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Early Onset

6. HUNTINGTON'S DISEASE MARKET TREATMENT OUTLOOK

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 6.1.2. Market Attractiveness Index, By Treatment
- 6.2. Symptomatic Treatment*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Disease-modifying Therapies

7. HUNTINGTON'S DISEASE MARKET ROUTE OF ADMINISTRATION OUTLOOK

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

7.1.2. Market Attractiveness Index, By Route of Administration

7.2. Oral*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Parenteral

7.4. Other

8. HUNTINGTON'S DISEASE MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

8.1.2. Market Attractiveness Index, By Region

8.2. North America

8.2.1. Introduction

8.2.2. Key Region-Specific Dynamics

8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.2.6.1. U.S.

8.2.6.2. Canada

8.2.6.3. Mexico

8.3. Europe

8.3.1. Introduction

8.3.2. Key Region-Specific Dynamics

8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.3.6.1. Germany

8.3.6.2. UK

8.3.6.3. France

8.3.6.4. Spain

8.3.6.5. Italy

8.3.6.6. Rest of Europe

8.4. Asia-Pacific

8.4.1. Introduction

8.4.2. Key Region-Specific Dynamics

8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.4.6.1. China

8.4.6.2. India

8.4.6.3. Japan

8.4.6.4. South Korea

8.4.6.5. Rest of Asia-Pacific

8.5. South America

8.5.1. Introduction

8.5.2. Key Region-Specific Dynamics

8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

8.5.5.1. Brazil

8.5.5.2. Argentina

8.5.5.3. Rest of South America

8.6. Middle East and Africa

8.6.1. Introduction

8.6.2. Key Region-Specific Dynamics

8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

9.1. Competitive Overview and Key Market Players

9.2. Market Share Analysis and Positioning Matrix

- 9.3. Strategic Partnerships, Mergers & Acquisitions
- 9.4. Key Developments in Product Portfolios and Innovations
- 9.5. Company Benchmarking

10. COMPANY PROFILES

Key Players

- 10.1. Teva Pharmaceutical Industries Ltd.*
 - 10.1.1. Company Overview
 - 10.1.2. Product Portfolio
 - 10.1.2.1. Product Description
 - 10.1.2.2. Product Key Performance Indicators (KPIs)
 - 10.1.2.3. Historic and Forecasted Product Sales
 - 10.1.2.4. Product Sales Volume
 - 10.1.3. Financial Overview
 - 10.1.3.1. Company Revenue
 - 10.1.3.2. Geographical Revenue Shares
 - 10.1.3.3. Revenue Forecasts
 - 10.1.4. Key Developments
 - 10.1.4.1. Mergers & Acquisitions
 - 10.1.4.2. Key Product Development Activities
 - 10.1.4.3. Regulatory Approvals, etc.
 - 10.1.5. SWOT Analysis
- 10.2. Bausch Health Companies Inc.
- 10.3. Neurocrine Biosciences, Inc.

Emerging Players

- 10.4. Annexon Inc.
- 10.5. AskBio Inc.
- 10.6. SOM Innovation Biotech S.A.
- 10.7. Prilenia Therapeutics B.V.
- 10.8. Sage Therapeutics

LIST NOT EXHAUSTIVE

11. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 11.1. Data Collection Methods
- 11.2. Data Triangulation
- 11.3. Forecasting Techniques
- 11.4. Data Verification and Validation

12. APPENDIX

12.1. About Us and Services

12.2. Contact Us

List Of Tables

LIST OF TABLES

Table 1 Global Huntington's Disease Market Value, By Disease Type, 2025, 2029 & 2033 (US\$ Million)

Table 2 Global Huntington's Disease Market Value, By Treatment, 2025, 2029 & 2033 (US\$ Million)

Table 3 Global Huntington's Disease Market Value, By Route of Administration, 2025, 2029 & 2033 (US\$ Million)

Table 4 Global Huntington's Disease Market Value, By Region, 2025, 2029 & 2033 (US\$ Million)

Table 5 Global Huntington's Disease Market Value, By Disease Type, 2025, 2029 & 2033 (US\$ Million)

Table 6 Global Huntington's Disease Market Value, By Disease Type, 2022-2033 (US\$ Million)

Table 7 Global Huntington's Disease Market Value, By Treatment, 2025, 2029 & 2033 (US\$ Million)

Table 8 Global Huntington's Disease Market Value, By Treatment, 2022-2033 (US\$ Million)

Table 9 Global Huntington's Disease Market Value, By Route of Administration, 2025, 2029 & 2033 (US\$ Million)

Table 10 Global Huntington's Disease Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 11 Global Huntington's Disease Market Value, By Region, 2025, 2029 & 2033 (US\$ Million)

Table 12 Global Huntington's Disease Market Value, By Region, 2022-2033 (US\$ Million)

Table 13 North America Huntington's Disease Market Value, By Disease Type, 2022-2033 (US\$ Million)

Table 14 North America Huntington's Disease Market Value, By Treatment, 2022-2033 (US\$ Million)

Table 15 North America Huntington's Disease Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 16 North America Huntington's Disease Market Value, By Country, 2022-2033 (US\$ Million)

Table 17 South America Huntington's Disease Market Value, By Disease Type, 2022-2033 (US\$ Million)

Table 18 South America Huntington's Disease Market Value, By Treatment, 2022-2033

(US\$ Million)

Table 19 South America Huntington's Disease Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 20 South America Huntington's Disease Market Value, By Country, 2022-2033 (US\$ Million)

Table 21 Europe Huntington's Disease Market Value, By Disease Type, 2022-2033 (US\$ Million)

Table 22 Europe Huntington's Disease Market Value, By Treatment, 2022-2033 (US\$ Million)

Table 23 Europe Huntington's Disease Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 24 Europe Huntington's Disease Market Value, By Country, 2022-2033 (US\$ Million)

Table 25 Asia-Pacific Huntington's Disease Market Value, By Disease Type, 2022-2033 (US\$ Million)

Table 26 Asia-Pacific Huntington's Disease Market Value, By Treatment, 2022-2033 (US\$ Million)

Table 27 Asia-Pacific Huntington's Disease Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 28 Asia-Pacific Huntington's Disease Market Value, By Country, 2022-2033 (US\$ Million)

Table 29 Middle East and Africa Huntington's Disease Market Value, By Disease Type, 2022-2033 (US\$ Million)

Table 30 Middle East and Africa Huntington's Disease Market Value, By Treatment, 2022-2033 (US\$ Million)

Table 31 Middle East and Africa Huntington's Disease Market Value, By Route of Administration, 2022-2033 (US\$ Million)

Table 32 Middle East and Africa Huntington's Disease Market Value, By Country, 2022-2033 (US\$ Million)

Table 33 Teva Pharmaceutical Industries Ltd.: Overview

Table 34 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 35 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 36 Bausch Health Companies Inc.: Overview

Table 37 Bausch Health Companies Inc.: Product Portfolio

Table 38 Bausch Health Companies Inc.: Key Developments

Table 39 Neurocrine Biosciences, Inc.: Overview

Table 40 Neurocrine Biosciences, Inc.: Product Portfolio

Table 41 Neurocrine Biosciences, Inc.: Key Developments

List Of Figures

LIST OF FIGURES

- Figure 1 Global Huntington's Disease Market Value, 2022-2033 (US\$ Million)
- Figure 2 Global Huntington's Disease Market Share, By Disease Type, 2024 & 2033 (%)
- Figure 3 Global Huntington's Disease Market Share, By Treatment, 2024 & 2033 (%)
- Figure 4 Global Huntington's Disease Market Share, By Route of Administration, 2024 & 2033 (%)
- Figure 5 Global Huntington's Disease Market Share, By Region, 2024 & 2033 (%)
- Figure 6 Global Huntington's Disease Market Y-o-Y Growth, By Disease Type, 2023-2033 (%)
- Figure 7 Adult Onset Huntington's Disease Market Value, 2022-2033 (US\$ Million)
- Figure 8 Early Onset Huntington's Disease Market Value, 2022-2033 (US\$ Million)
- Figure 9 Global Huntington's Disease Market Y-o-Y Growth, By Treatment, 2023-2033 (%)
- Figure 10 Symptomatic Treatment Treatment in Global Huntington's Disease Market Value, 2022-2033 (US\$ Million)
- Figure 11 Disease-modifying Therapies Treatment in Global Huntington's Disease Market Value, 2022-2033 (US\$ Million)
- Figure 12 Global Huntington's Disease Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
- Figure 13 Oral Route of Administration in Global Huntington's Disease Market Value, 2022-2033 (US\$ Million)
- Figure 14 Parenteral Route of Administration in Global Huntington's Disease Market Value, 2022-2033 (US\$ Million)
- Figure 15 Others Route of Administration in Global Huntington's Disease Market Value, 2022-2033 (US\$ Million)
- Figure 16 Global Huntington's Disease Market Y-o-Y Growth, By Region, 2023-2033 (%)
- Figure 17 North America Huntington's Disease Market Value, 2022-2033 (US\$ Million)
- Figure 18 North America Huntington's Disease Market Share, By Disease Type, 2024 & 2033 (%)
- Figure 19 North America Huntington's Disease Market Share, By Treatment, 2024 & 2033 (%)
- Figure 20 North America Huntington's Disease Market Share, By Route of Administration, 2024 & 2033 (%)
- Figure 21 North America Huntington's Disease Market Share, By Country, 2024 & 2033

(%)

Figure 22 South America Huntington's Disease Market Value, 2022-2033 (US\$ Million)

Figure 23 South America Huntington's Disease Market Share, By Disease Type, 2024 & 2033 (%)

Figure 24 South America Huntington's Disease Market Share, By Treatment, 2024 & 2033 (%)

Figure 25 South America Huntington's Disease Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 26 South America Huntington's Disease Market Share, By Country, 2024 & 2033 (%)

Figure 27 Europe Huntington's Disease Market Value, 2022-2033 (US\$ Million)

Figure 28 Europe Huntington's Disease Market Share, By Disease Type, 2024 & 2033 (%)

Figure 29 Europe Huntington's Disease Market Share, By Treatment, 2024 & 2033 (%)

Figure 30 Europe Huntington's Disease Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 31 Europe Huntington's Disease Market Share, By Country, 2024 & 2033 (%)

Figure 32 Asia-Pacific Huntington's Disease Market Value, 2022-2033 (US\$ Million)

Figure 33 Asia-Pacific Huntington's Disease Market Share, By Disease Type, 2024 & 2033 (%)

Figure 34 Asia-Pacific Huntington's Disease Market Share, By Treatment, 2024 & 2033 (%)

Figure 35 Asia-Pacific Huntington's Disease Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 36 Asia-Pacific Huntington's Disease Market Share, By Country, 2024 & 2033 (%)

Figure 37 Middle East and Africa Huntington's Disease Market Value, 2022-2033 (US\$ Million)

Figure 38 Middle East and Africa Huntington's Disease Market Share, By Disease Type, 2024 & 2033 (%)

Figure 39 Middle East and Africa Huntington's Disease Market Share, By Treatment, 2024 & 2033 (%)

Figure 40 Middle East and Africa Huntington's Disease Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 41 Teva Pharmaceutical Industries Ltd.: Financials

Figure 42 Bausch Health Companies Inc.: Financials

Figure 43 Neurocrine Biosciences, Inc.: Financials

I would like to order

Product name: Global Huntington's Disease Market - 2025-2033

Product link: <https://marketpublishers.com/r/G2BF0B653A37EN.html>

Price: US\$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2BF0B653A37EN.html>